Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Biogen Inc.
  6. News
  7. All News
    BIIB   US09062X1037

BIOGEN INC.

(BIIB)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
298.90 USD   -0.98%
12/01Health Care Up on Drug Development, M&A Hopes -- Health Care Roundup
DJ
12/01There are two ways to look at Powell's speech
MS
12/01Transcript : Biogen Inc. Presents at 5th Annual Evercore ISI HealthCONx Conference 2022, Dec-01-2022 10:30 AM
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
All news about BIOGEN INC.
12/01Health Care Up on Drug Development, M&A Hopes -- Health Care Roundup
DJ
12/01There are two ways to look at Powell's speech
MS
12/01Transcript : Biogen Inc. Presents at 5th Annual Evercore ISI HealthCONx Confe..
CI
12/01Atlantic Equities Adjusts Price Target on Biogen to $295 From $220, Maintains Neutral R..
MT
12/01UBS Adjusts Biogen Price Target to $338 From $319, Maintains Buy Rating
MT
12/01Analyst recommendations: Biogen, BAT, Hubbell, Liberty Global, P..
MS
11/30Stocks surge after Powell signals slower pace for rate hikes
RE
11/30Roche shutters most trials of Alzheimer's drug after failed trials
RE
11/30Stocks surge after Powell signals slower pace for rate hikes
RE
11/30Wall Street ends sharply higher after Powell comments
RE
11/30Health Care Up as Biogen, Horizon Surge -- Health Care Roundup
DJ
11/30Wall Street ends sharply higher after Powell comments
RE
11/30Biogen, Wayfair rise; CrowdStrike, NetApp fall
AQ
11/30Wall Street ends sharply higher after Powell comments
RE
11/30Eisai, Biogen Alzheimer's drug could be available to some next year
RE
11/30Wall Street rallies after Powell eyes slower rate hikes
RE
11/30Wall Street rises after Powell eyes slower rate hikes
RE
11/30Dow dips ahead of Powell speech; Nasdaq kept afloat by growth stocks
RE
11/30Global markets live: Apple, Tesla, Boeing, HP, Intuit...
MS
11/30Trending: Eisai/Biogen Alzheimer's Drug Shows Positive Results
DJ
11/30All eyes on Powell
MS
11/30Stifel Adjusts Price Target on Biogen to $331 From $299, Maintains Buy Rating
MT
11/30Jefferies Adjusts Price Target on Biogen to $350 From $325, Maintains Buy Rating
MT
11/30Alzheimer's drug slows decline but with side-effects
RE
11/30MarketScreener's World Press Review : November 30, 2..
MS
11/30Eisai - eleven experts from leading medical institutions and eight experts from eisai p..
AQ
11/30Eisai presents full results of lecanemab phase 3 confirmatory clarity ad study for earl..
AQ
11/30Wedbush Raises Biogen's Price Target to $247 From $218, Says Data Reinforces Likelihood..
MT
11/30Futures rise as focus turns to Powell speech
RE
11/30Barclays Raises Price Target on Biogen to $313 From $275, Keeps Equalweight Rating
MT
11/30Biogen, Eisai Say Lecanemab Reduces Clinical Decline in Early Alzheimer's Disease Phase..
MT
11/29Eisai, Biogen Alzheimer's drug slows cognitive decline, safety for some becomes focus
RE
11/29Japanese drugmaker Eisai's shares drop on report of death in Alzheimer's trial
RE
11/29Rare success for Alzheimer's research unlocks hope for future therapies
RE
11/29Biogen Shares Fall After Report of Death Linked to Potential Treatment for Alzheimer's ..
MT
11/29Japan Stocks Buried under Persistent US Monetary Tightening; Eisai Tanks 6% as Alzheime..
MT
11/29(OFFICIAL)-UPDATE 2-Japanese drugmaker Eisai's shares drop on report of death in Alzhei..
RE
11/28Eisai Shares Fall Following Report of Patient Death in Alzheimer's Trial
DJ
11/28Eisai shares plunge 10% in Tokyo after report of death in Alzheimer's trial
RE
11/28China Protests Spark Supply Concerns, Weighing on US Equities
MT
11/28China COVID Protests Spark Supply Chain Concerns, Weighing on US Equities
MT
11/28Wall Street ends down sharply, hit by Apple and China worries
RE
11/28Sector Update: Health Care Weakening Near Monday Close
MT
11/28Wall Street drops, weighed down by Apple and China worries
RE
11/28Wall Street drops, weighed down by Apple and China worries
RE
11/28Sector Update: Health Care Stocks Drifting Lower Monday Afternoon
MT
11/28Sector Update: Health Care
MT
11/28China COVID-19 Protests Weigh on US Equity Traders' Sentiment
MT
11/28US STOCKS-Apple, energy shares drag Wall St lower amid China COVID protests
RE
11/28China COVID-19 Protests Weigh on US Equities as Sentiment Sours Amid Growth Worries
MT
11/28Growing China COVID-19 Protests Weigh on Equities Amid Growth Worries
MT
11/28Biogen Shares Fall After Report of Death Linked to Potential Treatment for Alzheimer's ..
MT
11/28Wall St losses limited as Amazon gains on upbeat Cyber Monday
RE
11/28Soaring Covid cases in China spell trouble for global markets
MS
11/22Australia's CSL prices hemophilia gene therapy at $3.5 million
RE
11/21Teva Pharmaceutical Names Richard Francis as President, CEO
DJ
11/21Teva hires ex-Novartis executive to succeed CEO Schultz
RE
11/17Biogen : to Participate in the 5th Annual Evercore ISI HealthCONx Conference
PU
11/16MarketScreener's World Press Review : November 16, 2..
MS
11/15News Highlights: Top Company News of the Day
DJ
11/15Truist Securities Boosts Price Target on Biogen to $350 From $265, Maintains Buy Rating
MT
11/14Wall Street ends lower as investors gauge Fed's policy path
RE
11/14Moderna, Biogen rise; Oatly, Dentsply fall
AQ
11/14S&P 500 falls as investors gauge Fed's policy path
RE
11/14Wall Street moves higher as investors gauge Fed's policy path
RE
11/14S&P 500, Nasdaq pare losses as investors digest Fed comments
RE
11/14Global markets live: Softbank, Tyson Foods, Walt Disney, Tesla, Alib..
MS
11/14MarketScreener's World Press Review : November 14, 2..
MS
11/14Nasdaq leads Wall Street lower after hawkish Fed comments
RE
11/14Party pooper: Waller ends the rally
MS
11/14Oppenheimer Adjusts Biogen Price Target to $315 From $300, Maintains Outperform Rating
MT
11/14Wall St eyes lower open after hawkish Fed comments
RE
11/14Roche's Alzheimer's drug fails to meet goal in long awaited trial
RE
11/14Roche's Alzheimer's drug fails to meet goal in long awaited trial
RE
11/11Guggenheim Raises Price Target on Biogen to $270 From $265, Maintains Neutral Rating
MT
1  2  3  4  5  6  7  8  9  10Next
Upcoming event on BIOGEN INC.